Vir Biotechnology's Phase 3 ECLIPSE 1 trial in chronic hepatitis delta meets primary endpoint

Vir Biotechnology said its Phase 3 ECLIPSE 1 trial in chronic hepatitis delta met the primary endpoint, a key milestone for elebsiran and tobevibart in a high-unmet-need liver disease. More details are due on a conference call.

Detected & updated continuously · Source: Nebula